市場調査レポート

商品コード

1800975

α1アンチトリプシン欠乏症治療市場レポート：治療タイプ、投与経路、エンドユーザー、地域別、2025年～2033年

Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 123 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 446,910円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 595,930円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 744,950円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.02円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のα1アンチトリプシン欠乏症治療市場規模は2024年に22億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに42億米ドルに達し、2025年から2033年にかけて7.22%の成長率（CAGR）を示すと予測しています。

α-1抗トリプシン（AAT）欠損症は、体内でAATタンパク質が十分に生成されない遺伝的疾患を指します。AATタンパク質は、体内の他のタンパク質の悪影響から肺と肝臓を守るために不可欠です。重度のAAT欠乏症患者は、肝硬変、慢性閉塞性肺疾患（COPD）、肺気腫疾患を発症する可能性があります。遺伝子検査や血液検査で診断することができます。治療法としては、気管支拡張薬や副腎皮質ステロイドなどの薬を静脈注射や吸入する補強療法、肺リハビリテーション、酸素療法などがあります。

呼吸器疾患の有病率の増加は、市場の成長を促進する主な要因の1つです。さらに、補強療法が広く採用されていることも、市場の成長を後押ししています。この治療法では、患者の呼吸器内のAAT濃度を高めるために、健康なドナーの血漿からAATタンパク質を抽出します。これに伴い、この治療法は肺気腫の進行を遅らせ、増悪の頻度を最小限に抑え、回復速度を向上させる。加えて、診断法における様々な技術的進歩や、AATの生産・精製における革新的なプロセスの開発も、他の成長促進要因として作用しています。AATは品質が向上し、ウイルスや細菌などの汚染物質が含まれていないです。その他の要因としては、広範な研究開発（R&D）活動、医療インフラの改善などがあり、市場をさらに牽引すると予想されます。

本レポートで扱う主な質問

α1アンチトリプシン欠乏症治療市場の規模は？
α1アンチトリプシン欠乏症治療市場の将来展望は？
α1アンチトリプシン欠乏症治療市場を牽引する主要因は何か？
α1アンチトリプシン欠乏症治療市場で最大のシェアを占める地域は？
世界のα1アンチトリプシン欠乏症治療市場における主要企業は？

北米
- 米国
- カナダ
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ

第10章 SWOT分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章価格分析

第14章競合情勢

市場構造
主要企業
主要企業のプロファイル
- AstraZeneca PLC
- C.H. Boehringer Sohn AG & Ko. KG
- CSL Limited
- GlaxoSmithKline Plc
- Grifols S.A.
- Kamada Ltd.
- LFB Biomedicaments S.A.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.

図表

List of Figures

Figure 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Major Drivers and Challenges
Figure 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Treatment Type (in %), 2024
Figure 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Route of Administration (in %), 2024
Figure 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by End User (in %), 2024
Figure 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Region (in %), 2024
Figure 8: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: North America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: North America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: United States: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: United States: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: China: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: China: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: India: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: India: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: France: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: France: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 78: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: SWOT Analysis
Figure 79: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Value Chain Analysis
Figure 80: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
Table 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
Table 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Competitive Structure
Table 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Players

Product Code: SR112025A2467

The global alpha 1 antitrypsin deficiency treatment market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033.

Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.

The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor's blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Treatment Type:

Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
Others

Breakup by Route of Administration:

Parenteral
Inhalation
Oral

Breakup by End User:

Hospitals
Specialty Clinics
Others

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1.How big is the alpha 1 antitrypsin deficiency treatment market?
2.What is the future outlook of alpha 1 antitrypsin deficiency treatment market?
3.What are the key factors driving the alpha 1 antitrypsin deficiency treatment market?
4.Which region accounts for the largest alpha 1 antitrypsin deficiency treatment market share?
5.Which are the leading companies in the global alpha 1 antitrypsin deficiency treatment market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Alpha 1 Antitrypsin Deficiency Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Treatment Type

6.1 Augmentation Therapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Bronchodilators
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Corticosteroids
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Oxygen Therapy
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

7.1 Parenteral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Inhalation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Oral
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 AstraZeneca PLC
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 C.H. Boehringer Sohn AG & Ko. KG
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 CSL Limited
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
- 14.3.4 GlaxoSmithKline Plc
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Grifols S.A.
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 Kamada Ltd.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 LFB Biomedicaments S.A.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
- 14.3.8 Pfizer Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Takeda Pharmaceutical Company Limited
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
- 14.3.10 Teva Pharmaceutical Industries Ltd.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio

α1アンチトリプシン欠乏症治療市場レポート：治療タイプ、投与経路、エンドユーザー、地域別、2025年～2033年

Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2025-2033

本レポートで扱う主な質問

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のα1アンチトリプシン欠乏症治療市場

第6章 市場内訳：治療タイプ別

第7章 市場内訳：投与経路別

第8章 市場内訳：エンドユーザー別

第9章 市場内訳：地域別

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 価格分析

第14章 競合情勢